Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 4,680.00
-20.00 (-0.43%)
Jun 11, 2026, 3:30 PM KST
Oncocross Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 475.15 | 370.46 | 1,072 | 91.52 | 150.25 | 100 |
Other Revenue | - | - | - | - | - | -0 |
| 475.15 | 370.46 | 1,072 | 91.52 | 150.25 | 100 | |
Revenue Growth (YoY) | -55.77% | -65.45% | 1071.49% | -39.08% | 50.24% | 11.11% |
Cost of Revenue | 35.58 | 31.22 | 4.27 | 88.31 | 121.74 | 38.66 |
Gross Profit | 439.58 | 339.24 | 1,068 | 3.21 | 28.51 | 61.34 |
Selling, General & Admin | 5,139 | 4,849 | 4,563 | 3,412 | 3,636 | 4,258 |
Research & Development | 3,100 | 3,297 | 2,956 | 2,871 | 5,926 | 2,824 |
Amortization of Goodwill & Intangibles | 19.27 | 18.82 | 19.95 | 20.96 | 20.33 | 16.71 |
Other Operating Expenses | 204.75 | 211.48 | 107.61 | 96.63 | 99.84 | 63.54 |
Operating Expenses | 9,396 | 9,167 | 8,033 | 6,813 | 10,028 | 7,401 |
Operating Income | -8,957 | -8,828 | -6,965 | -6,810 | -9,999 | -7,339 |
Interest Expense | -878.61 | -526.27 | -18.79 | -38.31 | -76.49 | -5,341 |
Interest & Investment Income | 526.91 | 389.45 | 324.62 | 125.38 | 101.6 | 67.25 |
Currency Exchange Gain (Loss) | -0.4 | -0.48 | -2.17 | -6 | -3.35 | -1.21 |
Other Non Operating Income (Expenses) | -70.81 | -111.64 | 28.6 | 2,357 | -121.84 | -600.42 |
EBT Excluding Unusual Items | -9,379 | -9,077 | -6,633 | -4,372 | -10,099 | -13,215 |
Gain (Loss) on Sale of Investments | 100.57 | 178.18 | 149.39 | 265.78 | -85.56 | 68.5 |
Gain (Loss) on Sale of Assets | -29.79 | -29.79 | 0 | - | -19.19 | - |
Pretax Income | -9,309 | -8,929 | -6,483 | -4,106 | -10,204 | -13,146 |
Income Tax Expense | - | - | - | 108.26 | - | - |
Net Income | -9,309 | -8,929 | -6,483 | -4,214 | -10,204 | -13,146 |
Net Income to Common | -9,309 | -8,929 | -6,483 | -4,214 | -10,204 | -13,146 |
Shares Outstanding (Basic) | 12 | 12 | 10 | 9 | 9 | 5 |
Shares Outstanding (Diluted) | 12 | 12 | 10 | 9 | 9 | 5 |
Shares Change (YoY) | 10.92% | 14.17% | 17.54% | 1.44% | 63.74% | 0.83% |
EPS (Basic) | -774.05 | -746.72 | -619.00 | -472.98 | -1161.74 | -2450.70 |
EPS (Diluted) | -774.05 | -746.72 | -619.00 | -473.00 | -1161.74 | -2451.00 |
Free Cash Flow | -8,650 | -10,702 | -5,687 | -4,913 | -8,527 | -6,534 |
Free Cash Flow Per Share | -719.26 | -895.01 | -542.98 | -551.42 | -970.80 | -1218.13 |
Gross Margin | 92.51% | 91.57% | 99.60% | 3.51% | 18.98% | 61.34% |
Operating Margin | -1884.98% | -2383.02% | -649.58% | -7440.64% | -6655.30% | -7339.31% |
Profit Margin | -1959.09% | -2410.17% | -604.66% | -4604.70% | -6791.63% | -13146.17% |
Free Cash Flow Margin | -1820.41% | -2888.81% | -530.40% | -5368.32% | -5675.38% | -6534.38% |
EBITDA | -8,005 | -8,018 | -6,558 | -6,372 | -9,630 | -7,082 |
D&A For EBITDA | 951.96 | 809.92 | 406.66 | 438.4 | 369.13 | 257.59 |
EBIT | -8,957 | -8,828 | -6,965 | -6,810 | -9,999 | -7,339 |
Advertising Expenses | - | 266.46 | 113.9 | 31.53 | 123.36 | 97.13 |